Fledrich, R., R. M. Stassart, A. Klink, L. M. Rasch, T. Prukop, L. Haag, D. Czesnik, T. Kungl, T. A. M. Abdelaal, N. Keric, C. Stadelmann, W. Brück, K.-A. Nave and M. W. Sereda: Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. In: Nature Medicine 20, 9, 1055-1061 (2014).
Barrantes-Freer, A., E. Kim, J. Bielanska, A. Giese, L. S. Mortensen, W. Schulz-Schaeffer, C. Stadelmann, W. Brück and L. A. Pardo: Human glioma-initiating cells show a distinct immature phenotype resembling but not identical to NG2 glia. In: Journal of Neuropathology and Experimental Neurology 72, 4, 307-324 (2013).
Hohlfeld, R., M. Kerschensteiner, C. Stadelmann, H. Lassmann and H. Wekerle: The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis.. In: Neurological Science 27, S1-S7 (2006).
Diem, R., M. B. Sättler, D. Merkler, I. Demmer, K. Maier, C. Stadelmann, H. Ehrenreich and M. Bähr: Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. In: Brain 128, 375-385 (2005).
Sättler, M. B., D. Merkler, K. Maier, C. Stadelmann, H. Ehrenreich, M. Bähr and R. Diem: Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. In: Cell Death and Differentiation 11, Suppl. 2, S181-S192 (2004).
Kerschensteiner, M., C. Stadelmann, G. Dechant, H. Wekerle and R. Hohlfeld: Neurotrophic cross-talk between the nervous and immune systems: Implications for neurological diseases. In: Annals of Neurology 53, 3, 292-304 (2003).
The Max Planck Society does not take any responsibility for the content of this export.